Posology : מינונים

4.2 Posology and method of administration
Femoston-conti 0.5 mg/2.5 mg is a continuous combined HRT for oral use.
The estrogen and the progestogen are given every day without interruption.
The dosage is one tablet per day for a 28 day cycle.
Femoston-conti 0.5 mg/2.5 mg should be taken continuously without a break between packs.
For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.
Femoston is indicated for the treatment of symptoms and not for prevention.
In case of no improvement of symptoms within 3 months, treatment should be stopped Continuous combined treatment may be started with Femoston-conti 0.5 mg/2.5 mg depending on the time since menopause and severity of symptoms. Women experiencing a natural menopause should commence treatment with Femoston conti 0.5 mg/2.5 mg not earlier than at least 12 months after their last natural menstrual bleed. For surgically induced menopause, treatment may start immediately.
Depending on the clinical response, the dosage can subsequently be adjusted.
Patients changing from a continuous sequential or cyclical preparation should complete the 28 day cycle and then change to Femoston conti 0.5 mg/2.5 mg.
Patients changing from another continuous combined preparation may start therapy at any time If a dose has been forgotten, it should be taken as soon as possible. If more than 12 hours have elapsed, treatment should be continued with the next tablet without taking the forgotten tablet. The likelihood of breakthrough bleeding or spotting may be increased.
Femoston conti 0.5 mg/2.5 mg can be taken irrespectively of food intake.
Paediatric population:
There is no relevant indication for the use of Femoston conti 0.5 mg/2.5 mg in the paediatric population.